Tyler Collins

Tyler Collins has a diverse work experience spanning over several companies. Tyler currently holds the position of Senior Director, CMC Operations at Outlook Therapeutics, Inc. Tyler has been with the company since May 2022. Prior to this role, they served as the Director, CMC Operations at the same company from August 2020 to May 2022.

Before joining Outlook Therapeutics, Inc., Tyler worked at Prolong Pharmaceuticals from February 2012 to August 2020. During their time there, they held various roles including Director, Manufacturing & Process Development, Associate Director, Process Development & Manufacturing Sciences, Senior Manager, Process Development, Manager, Manufacturing, Manufacturing Scientist, and Scientist I.

Tyler also has experience working at Janssen, Pharmaceutical Companies of Johnson and Johnson. Tyler served as a Scientist at Eurofins-Lancaster Laboratories, Inc. and worked on site at Janssen Pharmaceuticals in Raritan, NJ. Tyler'sresponsibilities included capillary electrophoresis assay development and validation, authoring test methods, protocols, and technical documents.

In addition, Tyler has contributed to the innovative research at organizations like Church & Dwight, where they worked as a Post-Doctoral Consultant, and Duquesne University, where they served as a Post-Doctoral Consultant and Ph.D. Candidate/Graduate Research Assistant.

Tyler started their career as a Summer Intern at AstraZeneca, where they conducted radioligand binding assays in the Cellular Biochemistry department.

Overall, Tyler's work experience highlights their expertise in CMC operations, process development, manufacturing, and research in the pharmaceutical industry.

Tyler Collins completed their Bachelor of Science/Bachelor of Arts degree in Biochemistry/Chemistry and Biotechnology at Virginia Tech from 2001 to 2005. Tyler then pursued further education and obtained a Ph.D. in Biochemistry, Biophysical Chemistry, and Protein-Protein Interactions from Duquesne University from 2005 to 2009.